BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28272674)

  • 1. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
    Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
    Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
    de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
    Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
    Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
    Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
    Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
    Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
    Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
    Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
    Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
    Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
    Ostroumov E; Hunter CJ
    Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chordoma: Immunohistochemical Analysis of Brachury.
    Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
    Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) status in chordoma.
    Ptaszyński K; Szumera-Ciećkiewicz A; Owczarek J; Mrozkowiak A; Pekul M; Barańska J; Rutkowski P
    Pol J Pathol; 2009; 60(2):81-7. PubMed ID: 19886182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
    Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.
    Pan Y; Lu L; Chen J; Zhong Y; Dai Z
    J Orthop Surg Res; 2018 Apr; 13(1):76. PubMed ID: 29625617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine.
    Potluri S; Jefferies SJ; Jena R; Harris F; Burton KE; Prevost AT; Burnet NG
    Clin Oncol (R Coll Radiol); 2011 Apr; 23(3):199-208. PubMed ID: 20980136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
    Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
    World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
    Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
    Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.